CardioNXT has built a platform of products that enable a better understanding of complex cardiac arrhythmias such as Atrial Fibrillation, and furthermore deliver targeted therapy to affected areas within the heart. In addition to providing next generation technology, CardioNXT products are designed to reduce the cost of cardiac catheter ablation procedures. This attention to cost reduction will not only benefit the U.S. market, it will enable arrhythmia therapies to be adopted rapidly in global markets including underserved emerging markets.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
05/25/16 | $1,500,000 |
Solas Bioventures | undisclosed |